Interpretation of Two Indices for the Prediction of Cardiovascular Risk in Pediatric Obesity

Authors: Mustafa M. Donma, Orkide Donma

Abstract:

Obesity and weight gain are associated with increased risk of developing cardiovascular diseases and the progression of liver fibrosis. Aspartate transaminase–to-platelet count ratio index (APRI) and fibrosis-4 (FIB-4) were primarily considered as the formulas capable of differentiating hepatitis from cirrhosis. However, to the best of our knowledge, their status in children is not clear. The aim of this study is to determine APRI and FIB-4 status in obese (OB) children and compare them with values found in children with normal body mass index (N-BMI). A total of 68 children examined in the outpatient clinics of the Pediatrics Department in Tekirdag Namik Kemal University Medical Faculty were included in the study. Two groups were constituted. In the first group, 35 children with N-BMI, whose age- and sex-dependent BMI indices vary between 15 and 85 percentiles, were evaluated. The second group comprised 33 OB children whose BMI percentile values were between 95 and 99. Anthropometric measurements and routine biochemical tests were performed. Using these parameters, values for the related indices, BMI, APRI, and FIB-4, were calculated. Appropriate statistical tests were used for the evaluation of the study data. The statistical significance degree was accepted as p < 0.05. In the OB group, values found for APRI and FIB-4 were higher than those calculated for the N-BMI group. However, there was no statistically significant difference between the N-BMI and OB groups in terms of APRI and FIB-4. A similar pattern was detected for triglyceride (TRG) values. The correlation coefficient and degree of significance between APRI and FIB-4 were r = 0.336 and p = 0.065 in the N-BMI group. On the other hand, they were r = 0.707 and p = 0.001 in the OB group. Associations of these two indices with TRG have shown that this parameter was strongly correlated (p < 0.001) both with APRI and FIB-4 in the OB group, whereas no correlation was calculated in children with N-BMI. TRG are associated with an increased risk of fatty liver, which can progress to severe clinical problems such as steatohepatitis, which can lead to liver fibrosis. TRG are also independent risk factors for cardiovascular disease. In conclusion, the lack of correlation between TRG and APRI as well as FIB-4 in children with N-BMI, along with the detection of strong correlations of TRG with these indices in OB children, was the indicator of the possible onset of the tendency towards the development of fatty liver in OB children. This finding also pointed out the potential risk for cardiovascular pathologies in OB children. The nature of the difference between APRI vs. FIB-4 correlations in N-BMI and OB groups (no correlation vs. high correlation), respectively, may be the indicator of the importance of involving age and alanine transaminase parameters in addition to AST and PLT in the formula designed for FIB-4.

Keywords: APRI, FIB-4, obesity, triglycerides.

References:

[1] O. Donma, and M. Donma, “An indispensable parameter in lipid ratios to discriminate between morbid obesity and metabolic syndrome in children: high density lipoprotein cholesterol,” Int. J. Med. Health Sci., vol. 12, no. 5, pp. 224 – 228, 2018.
[2] M. Donma, and O. Donma, “Prominent lipid parameters correlated with trunk-to-leg and appendicular fat ratios in severe pediatric obesity,” Int. J. Med. Health Sci., vol. 16, no. 10, pp. 156-160, 2022.
[3] M. Donma, and O. Donma, “Associations between surrogate insulin resistance indices and the risk of metabolic syndrome in children,” Int. J. Med. Health Sci., vol. 14, no. 2, pp. 61-64, 2020.
[4] M. Donma, and O. Donma, “Links between inflammation and insulin resistance in children with morbid obesity and metabolic syndrome,” Int. J. Med. Health Sci., vol. 13, no. 5, pp. 219-222, 2019.
[5] M. Donma, and O. Donma, “The evaluation of complete blood cell count-based inflammatory markers in pediatric obesity and metabolic syndrome,” Int. J. Med. Health Sci., vol. 14, no. 3, pp. 89-92, 2020.
[6] O. Donma, and M. Donma, “The potential involvement of platelet indices in insulin resistance in morbid obese children,” Int. J. Med. Health Sci., vol. 14, no. 3,pp. 85-88, 2020.
[7] O. Donma, M. Donma, B. Nalbantoglu, B. Topcu, F. Tulubas, M. Aydin, T. Gokkus, and A. Gurel, “The importance of erythrocyte parameters in obese children,” Int. J. Med. Health Sci., vol. 9, no. 5; pp. 361-364, 2015.
[8] D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, Jul. 1985.
[9] P. Gunczler, and R. Lanes, “Relationship between different fasting-based insulin sensitivity indices in obese children and adolescents,” J. Pediatr. Endocrinol. Metab., vol. 19, no. 3, pp. 259-265, Mar. 2006.
[10] E. J. Cho, K. Han, S. P. Lee, D. W. Shin, and S. J. Yu, “Liver enzyme variability and risk of heart disease and mortality,” a nationwide population-based study, Liver Int. vol. 40, no. 6, pp. 1292-1302, Jun. 2020.
[11] B. Amernia, S. H. Moosavy, F. Banookh, and G. Zoghi, "FIB-4, APRI, and AST/ALT ratio compared to fibroscan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran," BMC Gastroenterol., vol. 3, no. 21(1), pp. 453, Dec. 2021.
[12] J. Rigor, A. Diegues, J. Presa, P. Barata, and D. Martins-Mendes, "Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and hepamet fibrosis score in a Portuguese population, " Postgrad. Med., vol. 134, no. 4, pp. 435-440, May. 2022.
[13] C. De Matteis, M. Cariello, G. Graziano, S. Battaglia, P. Suppressa, G. Piazzolla, C. Sabbà, and A. Moschetta. "AST to platelet ratio index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects," Sci. Rep., vol. 21, no. 11(1), pp. 14834, Jul. 2021.
[14] P. Małecki, M. Figlerowicz, P. Kemnitz, K. Mazur-Melewska, W. Służewski, and A. Mania, "Estimation of the risk of fibrosis in children with nonalcoholic fatty liver disease," Clin. Exp. Hepatol., vol. 6, no. 3, pp. 220-227, Sep. 2020.
[15] World Health Organization (WHO). The WHO child growth standards. 2016 June. Access: http://www.who.int/childgrowth/en/
[16] B. A. Sánchez-Jiménez, D. Brizuela-Alcántara, M. H. Ramos-Ostos, L. F. Alva-López, M. Uribe-Esquivel, and N. C. Chávez-Tapia, “Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis,” Alcohol., vol. 69, pp. 63-67, Jun. 2018.
[17] H. Moran-Lev, S. Cohen, M. Webb, A. Yerushalmy-Feler, A. Amir, D. L. Gal, and R. Lubetzky, “Higher BMI predicts liver fibrosis among obese children and adolescents with NAFLD - an interventional pilot study,” BMC Pediatr., vol. 3, no. 21(1), pp. 385, Sep. 2021.
[18] P. B. Duell, F. K. Welty, M. Miller, A. Chait, G. Hammond, Z. Ahmad, D. E. Cohen, J. D. Horton, G. S. Pressman, and P. P. Toth, “American heart association council on arteriosclerosis, thrombosis and vascular biology; council on hypertension; council on the kidney in cardiovascular disease; council on lifestyle and cardiometabolic health; and council on peripheral vascular disease. nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association,” Arterioscler. Thromb. Vasc. Biol., vol. 42, no. 6, pp. e168-e185, Jun. 2022.
[19] M. A. de Carli, L. A. de Carli, M. B. Correa, G. Jr. Junqueira, C. V. Tovo, and G. P. Coral, “Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease,” Eur. J. Gastroenterol. Hepatol., vol. 32, no. 3, pp. 420-425, Mar. 2020.
[20] C. N. Didoné Filho, C. J. Reginatto, C. A. P. Ivantes, R. Strobel, A. P. Percicote, M. Petenusso, C. J. R. Sobreira da Silva, C. J. R. Benjamim, and R. B. Radominski, “Comparison between non-invasive methods and liver histology to stratify liver fibrosis in obese patients submitted to bariatric surgery,” Obes. Res. Clin. Pract., vol. 15, no. 2, pp. 152-156, Mar.-Apr. 2021.
[21] R. de Cleva, L. F. Duarte, M. R. F. Crenitte, C. P. M. de Oliveira, D. Pajecki, and M. A. Santo, “Use of noninvasive markers to predict advanced fibrosis/cirrhosis in severe obesity,” Surg. Obes. Relat. Dis., vol. 12, no. 4, pp. 862-867, May. 2016.
[22] S. M. Schmitz, A. Kroh, T. F. Ulmer, J. Andruszkow, T. Luedde, J. F. Brozat, U. P. Neumann, and P. H. Alizai, “Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems,” BMC Gastroenterol., vol. 5, no. 20(1), pp. 254, Aug. 2020.
[23] M. B. B. E. Silva, F. Tustumi, A. C. B. Dantas, B. C. J. Miranda, D. Pajecki, R. de-Cleva, M. A. Santo, and S. C. Nahas, “Obesity and severe steatosis: the importance of biochemical exams and scores,” Arq. Bras. Cir. Dig., vol. 31, no. 34(4), pp. e1626, Jan. 2022.
[24] E. Kim, Y. Kang, S. Hahn, M. J. Lee, Y. N. Park, and H. Koh, “The efficacy of aspartate aminotransferase-to-platelet ratio index for assessing hepatic fibrosis in childhood nonalcoholic steatohepatitis for medical practice,” Korean J. Pediatr., vol. 56, no. 1, pp. 19-25, Jan. 2013.
[25] A. E. Rigamonti, A. Bondesan, E. Rondinelli, S. G. Cella, and A. Sartorio, “The role of aspartate transaminase to platelet ratio index (APRI) for the prediction of non- alcoholic fatty liver disease (NAFLD) in severely obese children and adolescents,” Metabolites. vol. 8. no. 12(2), pp. 155, Feb. 2022.
[26] A. Sert, O. Pirgon, E. Aypar, H. Yilmaz, and B. Dundar, “Relationship between aspartate aminotransferase-to-platelet ratio index and carotid intima-media thickness in obese adolescents with non-alcoholic fatty liver disease,” J. Clin. Res. Pediatr. Endocrinol., vol. 10, no. 5(3), pp. 182-188, Sep. 2013.
[27] I. Graupera, M. Thiele, M. Serra-Burriel, L. Caballeria, D. Roulot, G. L. Wong, N. Fabrellas, I. N. Guha, A. Arslanow, C. Expósito, R. Hernández, G. P. Aithal, P. R. Galle, G. Pera, V. W. Wong, F. Lammert, P. Ginès, L. Castera, and A. Krag, “Investigators of the liverscreen consortium. low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population,” Clin. Gastroenterol. Hepatol., vol. 29, no. S1542-3565(21), pp. 1358-1366, Dec. 2021.
[28] S. Qadri, N. Ahlholm, I. Lønsmann, P. Pellegrini, A. Poikola, P. K. Luukkonen, K. Porthan, A. Juuti, H. Sammalkorpi, A. K. Penttilä, R. D'Ambrosio, G. Soardo, D. J. Leeming, M. Karsdal, J. Arola, S. Kechagias, S. Pelusi, M. Ekstedt, L. Valenti, H. Hagström, and H. Yki-Järvinen. “Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease,” J. Clin. Endocrinol. Metab., vol. 19, no. 107(5), pp. e2008-e2020, Apr. 2022.
[29] A. Drolz, S. Wolter, M. H. Wehmeyer, F. Piecha, T. Horvatits, J. Schulze Zur Wiesch, A. W. Lohse, O. Mann, and J. Kluwe, “Performance of non-invasive fibrosis scores in non- alcoholic fatty liver disease with and without morbid obesity,” Int. J. Obes. (Lond)., vol. 45, no. 10, pp. 2197-2204, Oct. 2021.
[30] J. H. M. Lum, M. C. C. Cheah, W. Q. Leow, W. K. Wan, T. K. H. Lim, W. C. Chow, J. P. E. Chang, and G. B. B. Goh, “Clinical profile of non-alcoholic fatty liver disease in nonobese patients,” J. Gastroenterol. Hepatol., vol. 36, no. 1, pp. 257-261, Jan. 2021.
[31] K. Thanapirom, S. Suksawatamnuay, N. Tanpowpong, B. Chaopathomkul, S. Sriphoosanaphan, P. Thaimai, N. Srisoonthorn, S. Treeprasertsuk, and P. Komolmit,. “Non- invasive tests for liver fibrosis assessment in patients with chronic liver diseases: a prospective study,” Sci. Rep., vol. 22, no. 12(1), pp. 4913, Mar. 2022.
[32] S. A. Alqahtani, P. Golabi, J. M. Paik, B. Lam, A. H. Moazez, H. A. Elariny, Z. Goodman, and Z. M. Younossi, “Performance of noninvasive liver fibrosis tests in morbidly obese patients with nonalcoholic fatty liver disease,” Obes. Surg., vol. 31, no. 5, pp. 2002-2010, May. 2012.
[33] Y. Kim, Y. Chang, Y. K. Cho, J. Ahn, H. Shin, and S. Ryu. “Obesity and weight gain are associated with progression of fibrosis in patients with nonalcoholic fatty liver disease,” Clin. Gastroenterol. Hepatol., vol. 17, no. 3, pp. 543-550.e2., Feb. 2019.